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Abstract 
In our previous study, a rat homologue of human nonmuscle myosin heavy chain-
B (nmMHC-B) was identified by mRNA differential display comparing of 
transformed against nontransformed Rat 6 cells overexpressing mutant p53val135 
gene.  The nmMHC-B was found to be expressed in normal Rat 6 embryo 
fibroblast cell line, but markedly suppressed in the mutant p53val135-transformed 
Rat 6 cells.  To examine the possible involvement of nmMHC-B in cell 
transformation, we first cloned and sequenced the full length cDNA of rat 
nmMHC-B, which was then cloned into an ecdysone-expression vector.  The 
resulting construct was introduced into the T2 cell line, a mutant p53val135-
transformed Rat 6 cells lacking the expression of the endogenous nmMHC-B.  
The clonal transfectants, expressing muristerone A-induced nmMHC-B, displayed 
a slightly flatter morphology and reached to a lower saturation density compared 
to the parental transformed cells.  Reconstitution of actin filamental bundles was 
also clearly seen in cells overexpressing the nmMHC-B. In soft agar assays, 
nmMHC-B transfectants formed fewer and substantially smaller colonies than the 
parental cells in response to muristerone A induction.  Moreover, it was strikingly 
effective in suppressing the tumorigenicity of the T2 cells when tested in nude 
mice.  Thus, the nmMHC-B, known as a component of the cytoskeletal network, 
may act as a tumor suppressor gene.  Our current finding may reveal a novel role 
of nmMHC-B in regulating cell growth and cell signaling in nonmuscle cells. 
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Introduction 
Myosin, a cytoskeletal protein conserved among all eukaryotic cells, plays a 
major role in muscle contraction.  The conventional myosin (class II myosin) 
molecule possesses a hexameric structure composed of one pair of heavy chains 
of approximately 200 kD and two pairs of light chains of about 15-28 kD.  
Myosin is expressed in both muscle and non-muscle cells.  The role of myosin in 
muscle contraction is well known, whereas the function of myosin in nonmuscle 
cells is less clear.  Evidence suggests that myosin plays a role in cytokinesis (De 
Lozanne and Spudich, 1987), cell proliferation (Rovner et al., 1986; Simons et al., 
1992), secretion (Ludowyke et al., 1989) and migration (Warrick and Spudich, 
1987).  Defects in myosins are thought to be associated with several genetics 
lesions (for review see Gulick and Rayment, 1997).  Two major isoforms of 
nonmuscle myosin heavy chain A and B (nmMHC-A and -B) have been identified 
in vertebrate cells.  The cDNAs of nmMHC have been cloned from human, 
mouse, chicken, and xenopus (Choi et al., 1996; Phillips et al., 1995; Saez et al., 
1990; Katsuragawa et al., 1989; Bhatia-Dey et al., 1993).  A recent study 
indicates that nmMHC-B is required for normal development of mouse heart and 
that its absence results in abnormal development of cardiac myocyte (Tullio et al., 
1997).  Unique forms of isoform B have also been identified in chicken and 
human neuronal cells (Takahashi et al., 1992; Itoh and Adelstein, 1995) and was 
reportedly involved in neuronal differentiation.  A study by Mummert and 
Schenground (1997) indicated that nmMHC-B has a function in neurite formation.   
In our recent effort to elucidate the role of the mutant p53 gene in 
neoplastic transformation, a temperature sensitive mutant p53val135 (valine at 
position 135) was introduced into normal Rat 6 embryo fibroblasts that retained 
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the endogenous wild type p53.  One of the resulting p53val135-overexpressors, 
R6#13-8, showed no obvious alteration in growth properties; however, they did 
exhibit frequent spontaneous transformation in prolonged cultures.  The T2 clonal 
cell line, derived from one of the spontaneous transformed foci of R6#13-8 
cultures, showed typical transforming morphology and formed tumors in nude 
mice.  In addition, the cells no longer expressed the vectored p53, suggesting 
secondary changes occurred in these cells leading to cell transformation (Yam et 
al., 1999).  In an effort to identify events related to mutant p53val135-induced 
malignant phenotypes, R6#13-8, and its derived spontaneous transformant T2 cell 
line were employed for mRNA differential display.  After a systematic screening 
with 80 sets of primers, three significant cDNA fragments (Yam et al., 1999) 
were identified. One of these was a 351-bp fragment found down-regulated in T2 
and it shared 93% homology with the 3' terminus of the human nmMHC-B gene.  
Using the 351 bp fragment as a probe in a Northern blot analysis, a 7.6 kb 
transcript corresponding to the reported human nmMHC-B was detected among 
the normal Rat 6, untransformed Rat 6 derivatives overexpressing p53val135, but 
not in the spontaneous transformants derived from R6#13-8 cultures.  The levels 
of transcript seem to be inversely correlated with the degree of transformation of 
the tested cell lines.   
Although nmMHC-B is involved in diverse cellular functions, there is no 
indication that it participates in cell transformation. Early studies on cytoskeletal 
proteins such as actin, tropomyosin and vinculin have provided evidence that 
reduction of cytoskeletal proteins are often a key feature of cell transformation 
(for a review, see Ben-Ze’ev, 1997).  Later studies also showed that 
overexpression of α-actinin, vinculin or tropomyosin could reverse transforming 
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phenotypes of certain transformed cells (Glück et al., 1993; Fernández et al. 1992, 
Boyd et al., 1995). Moreover, an interesting notion has emerged that some cell 
adhesion molecules, known to be intimately associated with cytoskeletal network, 
may work as tumor suppressors (Tsukita et al., 1993).  All these observations 
prompt us to hypothesize that suppression of nmMHC-B in T2 cells might 
contribute in part to the malignant phenotypes of T2 cells, which may be reversed 
by re-introducing the gene back to the cells.  
To investigate the role of nmMHC-B in cell transformation, T2 
transformed cells that expressed negligent levels of nmMHC-B were transfected 
with the rat nmMHC-B (designated as r-nmMHC-B) gene under an ecdysone 
expression system.  Results showed that overexpression of r-nmMHC-B slightly 
flattened cell morphology, lowered saturation densities and partially reversed the 
anchorage-independent growth of T2 cells. Intriguedly, r-nmMHC-B transfected 
T2 cells were non-tumorigenic when inoculated into nude mice.  Based on this 
observation, r-nmMHC-B may act as a tumor suppressor gene at least in cells 
transformed by the mutated p53 tumor suppressor gene.  
 
Results 
Suppression of nmMHC-B, but not -A isoform was observed in spontaneous 
transformant T2 cell line.  
In organisms and cell types studied so far, the conventional myosin II consists of 
two major isoforms, MHC-A and -B, encoded by different genes (Simons et al., 
1991).  Using A- and B- specific polyclonal antibodies as probes, the extracts of 
Rat 6, R6#13-8, and T2 cells were analyzed by immunoblotting (Fig. 1A).  The 
nmMHC-A and -B both yield proteins with 220 kD in size.  In order to verify the 
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specificity of each antibody, Cos7 cells (known to express only B isoform), and 
human serum platelets (known to express only A isoform) were included in the 
study as positive controls.  Interestingly, the expression of A-isoform is 
unaffected in the T2 cell line.  Similar results were obtained by 
immunofluorescent staining (Fig. 1B).  Although both isoforms are coexpressed 
in most cell types, lacking expression of one or the other isoform has no apparent 
effect on cell viability as evidenced by the growth of T2, Cos7 cells and others, 
such as the rat mast cell line RBL-2H3 described by Choi et al. (1996). 
 
Cloning of the full-length rat nmMHC-B cDNA.   
To confirm and further characterize the putative gene homologous to nmMHC-B, 
the 351 bp rat cDNA fragment previously identified was used as a probe to screen 
a rat brain cDNA library (Stratagene #936501).  Two isolated overlapping 
positive clones provide sequence information for a 7648 bp full length cDNA of 
r-nmMHC-B (GenBank AF139055), which consists of an open reading frame of 
5928 bp coding region, preceded by 188 nucleotides and tailed with 1532 bp of 
untranslated region. Compared the homologues of human and chicken (GenBank 
M69181) (Phillips et al., 1995) & (GenBank M93676) (Katsuragawa et al., 1989), 
the rat homologue has a longer 5’ untranslated region (UTR), which might be 
derived from a minor upstream transcription initiation site, as suggested by Weir 
and Chen (1996).  The 3' UTR is 69% homology to the human sequences (Phillips 
et al., 1995), however, there are two stretches of sequences (6226-6707 & 6941-
7620) which share 86% and 78% to those of human, suggesting that the well 
conserved 3' UTR may play an important role in regulating nmMHC-B function.  
The r-nmMHC-B exhibit 99 and 96% homology in amino acid sequences, and 89 
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and 83% homology in nucleotide sequences, to human and chicken respectively 
(Phillips et al., 1995; Katsuragawa et al., 1989).  The deduced amino acid 
sequences of r-nmMHC-B were compared to those from human and chicken 
shown in Fig. 2.  The reported unique sequence insertions (Takahashi et al., 1992; 
Itoh et al., 1995) are not found in r-nmMHC-B.   
 
Construction and expression of r-nmMHC-B vector in T2 cells.   
To address whether the suppression of nmMHC-B in T2 cells might have 
contributed to its acquired transforming phenotypes, the full length r-nmMHC-B 
cDNA was cloned into pIND/Hygro vector, which contains the ecdysone response 
element sequences and the hygromycin gene.  The resulting vector 
pIND/nmMHC-B together with the vector pVgRXR carrying both the retinoid X 
receptor and an ecdysone receptor and a zeocin gene were cotransfected into T2 
cells, followed by zeocin and hygromycin selections.  Two stable transfectants, 
T2/MHC-B#33 (MHC#33) and T2/MHC-B#44 (MHC#44), which showed 
inducible nmMHC-B expression upon induction in a dosage dependent manner 
(Fig. 3A) were selected for later study.  A T2 derivative-T2C expressing only the 
pIND and pVgRXR backbone vectors was also established as a control cell line.  
Based on the screenings on nmMHC-B expression, all the tested transfectants 
showed basal levels of nmMHC-B in the absence of the inducer, indicating that 
there is a leakage in the system. In general, MHC#44 displays lower background 
level of nmMHC-B under uninduced condition and is more responsive upon 
muristerone A induction compared to the MHC#33 clone (Fig. 3A).  Neither the 
parental T2 nor T2C expresses any detectable nmMHC-B protein. 
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With regard to morphology, the parental T2 and vectors-expressing T2C 
cells showed a typical transforming morphology with short, refractile cell bodies 
that were densely packed, while the stable MHC-B transfectants displayed a 
slightly flattened morphology in the absence of inducer (Fig. 3B). MHC#44 was 
flatter than MHC#33.  Addition of muristerone A seemed to further flatten the 
morphology of both clones slightly, while imposed no effect on T2 or T2C cells 
(Fig. 3B).  
 
Immunofluorescent localization of nmMHC-B in the transfectants.   
We then further characterized MHC#44 by immunofluorescent staining and 
observed that the subcellular distribution of the exogenous r-nmMHC-B was quite 
different from that observed in Rat 6 or R6#13-8 cells (Fig. 3C).  In Rat 6 cells, 
the endogenous nmMHC-B was diffusely throughout the cytoplasm, whereas the 
exogenous r-nmMHC-B was densely accumulated around the nuclear envelope of 
MHC#44, irrespective of stages of cell growth or division, which became more 
prominent upon addition of the inducer.  As expected, nmMHC-B is not 
detectable in T2 cells, induced or uninduced (Fig. 3C). 
 
The nmMHC-B-expressing cells showed reduction in saturation density and 
anchorage-independent growth.   
The effect of nmMHC-B on growth rate and saturation density was examined in 
MHC#44 clone.  Figure 4A shows growth curves of MHC#44 cells in the absence 
or presence of 2, 5, & 10 μM of muristerone A.  There are no apparent differences 
in growth rate among the experimental groups; however, the saturation density 
was steadily decreased as the concentrations of inducer steadily increased. Early 
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western blotting showed that the induced level of r-nmMHC-B was proportionally 
correlated with the dosage of the applied inducer.  In the same experiment, a 
single “day 8” time point of T2 cells in the absence or presence of 10 μM inducer 
was included.  The saturation density of MHC#44 reached only 46% and 32 % of 
the control T2 cells in both uninduced and induced conditions.  To ensure that the 
growth retardation observed in MHC#44 cells was not simply due to the 
nonspecific toxic effect of muristerone A, T2 and MHC#44 were treated with 
various dosages of muristerone A for 8 days, and then were counted for cell 
number.  Compared to the untreated T2 cells, the treated T2 show 15 and 17% 
growth reduction, whereas MHC#44 cells show 50 and 58% reduction under the 
treatment of 5 and 10 μM muristerone A, respectively (Fig. 4A).  Despite the fact 
that muristerone A was slightly toxic at high concentration, the growth inhibition 
seen in MHC#44 cells was much more striking than in the T2 cells.  We therefore 
conclude that reduced saturation density was mainly due to the effect of r-
nmMHC-B expressed in MHC#44 cells.  It is worth mentioning that there was no 
obvious cell death in the induced cultures, suggesting that overexpression of r-
nmMHC-B might have restored the contact inhibition property of the T2 cells, but 
did not exert a direct killing effect on cells.  In fact, the r-nmMHC-B expressing 
cells appeared healthy, although somewhat slow growing, under high dosages of 
muristerone A.  
To investigate the effect of nmMHC-B on the malignant phenotypes of the 
T2 cells in vitro, the uninduced and induced MHC#44 cells were examined for 
anchorage-independent growth in semi-soft agar as described (Housey et al., 
1988).  Rat 6 and R6#13-8 were also included for comparison.  As shown in 
Figure 4B and Table 1, normal Rat 6 cells remained as single cells; R6#13-8 cells 
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formed few small colonies; while T2 transformants formed numerous large 
colonies.  The uninduced MHC#44 cells, which constitutively expressed low 
levels of nmMHC-B, formed similar numbers, but much smaller colonies than the 
parental T2 cells (Fig. 4C and Table 1). MHC#44 cultures induced with 1 μM and 
5 μM of muristerone A, respectively, showed significant reductions both in 
numbers and sizes of agar colonies. These results indicate that the induced 
expression of r-nmMHC-B is responsible for the partial reversion of the 
anchorage independent growth of the T2 cells.  
 
Reconstitution of actin filaments in T2 cells overexpressing r-nmMHC-B. 
Disruption of cytoskeletal network is one of the characteristic features of cell 
transformation, irrespective of the course of transformation.  To examine the 
status of the cytoskeletal structure, we stained the actin filaments of R6, R6#13-8, 
T2C, and MHC#44 with FITC-phalloidin, a phallotoxin that binds to filamentous 
actin.  Like other non-transformed cells, the actin cable network was preserved in 
normal R6 and non-transformed R6#13-8 cells, but not in the fully transformed 
T2C (Fig. 5A-C).  On the other hand, the MHC#44 cells, which displayed 
reversed transforming phenotypes, have nicely restored the actin filamentous  
system that was lost in the T2C cells lacking the expression of nmMHC-B (Fig. 
5D).  Treatment with muristerone A did not significantly enhance the actin 
filament bundles further in any of the test cell lines.  In fact, under uninduced 
condition, the intensity of the actin bundles in MHC#44 seemed to be the same, 
except, they were less orderly compared to the actin filaments in R6 and R6#13-8 
cells.  This partial restoration of actin organization of MHC#44 is in line with the 
partial reversed transforming phenotypes described above in this report.  
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r-nmMHC-B suppresses tumorigenicity of T2 cells.    
Data above suggested that expression of r-nmMHC-B in T2 partially reversed its 
transforming phenotypes, namely the cell morphology, saturation density and 
anchorage independent growth, and actin filaments.  We therefore performed in 
vivo tumorigenicity tests in nude mice to assess the transforming status of 
MHC#44.  Prior to the injection, MHC#44 cells were induced with or without 10 
μM muristerone A for 48 hr.  To preclude any adverse effect of muristerone A on 
animals, T2 cells induced by same dosage of muristerone A were included in the 
experiment, in addition to the uninduced.  At the end of treatment, cells were 
harvested and washed once with cold PBS, then resuspended in PBS and counted.  
For each group, three injection sites, each with 3x106 cells, were performed.  
Results of such experiment are shown in Figure 6 and Table 2 (Expt. I).  T2 cells, 
treated or untreated with muristerone A, induced palpable tumors in all sites one 
week after the injections, and the tumors rapidly grew to sizes ranging from 2 to 
7.5 cm3 by the end of the second week, when mortality began to be seen among 
the tumor bearing animals.  In contrast, no tumor was detected at the sites injected 
with r-nmMHC-B expressors, either induced or uninduced.  At the end of two 
weeks, a small palpable lump was observed at one of the injection sites with 
uninduced r-nmMHC-B expressors, and this was later verified by surgical 
examination.  Suppression of malignant transformation by nmMHC-B was very 
striking, especially in view of the low level of nmMHC-B in the uninduced cells.  
To verify the anti-turmorigenic activity of r-nmMHC-B, we carried out another 
nude mice assay on two transfectants: MHC#44 and #33 under induced and 
uninduced conditions.  Once again, MHC#44 produced no tumor (Table 2, Expt. 
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II), while T2 gave rise to large tumors within two weeks.  MHC#33 induced 
tumors at all injection sites; however, tumor size was significantly smaller than in 
the control group.  T2C, the backbone vectors clone, when injected into nude 
mice, produced large tumors ranging from 4.8 to 6.7 cm3 under both induced and 
uninduced situations within the same latency period as the parental T2 cells. 
 
Discussion 
In this report, we described the cloning and characterization of a rat homologue to 
the known nmMHC-B gene. This homologue was previously found down-
regulated in transformed cells which had arisen spontaneously in the mutant 
p53val135-overexpressing Rat 6 fibroblasts (Yam et al., 1999).  Upon acquiring the 
full length cDNA sequences, we subsequently constructed a r-nmMHC-B 
expression vector driven by an ecdysone-inducible promoter; the r-nmMHC-B 
vector was then introduced back to one of the spontaneous transformant T2 cells 
lacking the expression of nmMHC-B, but not of -A.  The restoration of the r-
nmMHC-B expression in T2 partially reversed the transforming phenotypes of T2 
cells in terms of cell morphology, saturation density, and anchorage-independent 
growth in an ecdysone-dependent fashion.  The actin network, a key feature in 
cell transformation, clearly reappeared, which provides a strong indication of the 
reversion of transforming phenotypes.  Furthermore, expression of r-nmMHC-B 
in T2 drastically suppressed the tumorigenic activity of T2 tested in nude mice.   
It might seem surprising to observe such strong anti-tumor effects with both r-
nmMHC-B transfectants in the uninduced condition where little leakage of r-
nmMHC-B was detected, and when the difference between the T2 and uninduced 
MHC#44 in soft agar growth was rather mild (difference in size, but not in terms 
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of number of colonies); however, such discrepancy between anchorage 
independence growth and tumorigenicity has been documented elsewhere (for 
review, see Stanbridge & Wilkinson, 1980).  This may well be a phenotypic trait 
unique to nmMHC-B-expressing cells. 
  In addition to the novel tumor suppression effect of r-nmMHC-B, the 
other intriguing finding in the current study is the unusual subcellular distribution 
of the ecdysone-inducible r-nmMHC-B. Endogenous nmMHC-B is evenly 
distributed in the cytoplasm of normal Rat 6 or untransformed R6#13-8 cells, 
while vectored nmMHC-B is distinctly localized in the nuclear membrane of 
MHC#44, becoming even more prominent in the presence of inducer (Fig. 3C).  
According to the study in xenopus (Kelly et al., 1996), nmMHC-B is present in 
the cell cortex and diffusely distributed in the cytoplasm; this concurs with our 
observation in Rat 6 and R6#13-8 cells. During prophase, the nmMHC-B 
distributes to the nuclear membrane.  However, unlike the finding in our study, 
they reported that xenopus nmMHC-B resumed its interphase localization by 
metaphase, while our vectored r-nmMHC-B distributed to the nuclear membrane 
at all stages of cell cycle.  It was suggested by the authors that nmMHC-B may be 
involved in nuclear envelope breakdown in prophase.  Along this line, it is 
generally believed that both nmMHC-A and -B, together with actin filaments, are 
likely the crucial components of the contractile ring during cytokinesis.  
Nevertheless, the growth rates of both nmMHC-B- expressing cells and depleted 
cells are the same (Fig. 4A).  Later, we performed flow cytometer analysis of cell 
cycle on both cell lines and found no significant difference, indicating that the 
overexpression of nmMHC-B had no adverse effect on cell cycle progression 
(data not shown).   
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Although, prior to our current study, there has been no report of tumor 
suppression activity of nmMHC (or by any member of the myosin family) (Hall, 
1998), numerous studies have revealed that malignant transformations are often 
accompanied by disruption in cytoskeletal and adhesion proteins including actin, 
tropomyosin, vinculin, α-actinin.  Restoration of the cytoskeletal network through 
gene transfer could reverse the transforming phenotypes, i.e. cell shape, cell 
adhesion, saturation density, anchorage- independent growth and tumorigenicity 
(Glück et al., 1993; Fernández et al. 1992, Boyd et al., 1995; Gimona et al., 1996). 
Because myosin is a key member in the actin microfilament network, it is 
conceivable, and was also shown in our study, that ectopic expression of myosin 
could alter the growth properties and tumorigenicity in a  way similar to those 
observed with other actin-dependent proteins.   At this point, whether 
reappearance of actin bundles is simply a marker for a reversed transforming 
phenotype, or whether it is a direct result of r-nmMHC expression is not known; 
however, few reports have pointed out that myosin plays a primary role in the 
alignment of actin filaments, and, conversely, that inactivation of the protein 
results in disassembly of actin organization (Lamb et al., 1988; Honer, 1988; 
Fukui et al., 1990).  Along this line, recent study again showed that 
microinjection of myosin into REF 52 rat fibroblasts initiated the formation of 
actin filament bundles in the lamellae (Verhovsky et al., 1995).   Thus, 
reexpression of myosins in T2 cells might indeed trigger assembly of actin 
filaments, which in turn would alter the transforming phenotypes of the cells. 
Despite the clear association between tumor suppression and the assembly 
of cytoskeletal proteins and of related adhesion proteins in general, the underlying 
mechanism of the suppression remains obscure.  Recent studies on oncogenes and 
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tumor suppressor genes and their roles in signal transduction have revealed the 
link between adhesion plaques and key signaling pathways where various tumor 
suppressor genes and oncogenes are strategically located and where they 
coordinate rigorous checks and balances on cell signaling for growth and 
differentiation (for review see Hunter, 1997).  Most recently, an emerging theme 
in the field of cytoskeletal research is that the ability of Rho/Rac family proteins 
in regulating the actin cytoskeleton through direct targeting of the myosin light 
chains, which regulate the myosin heavy chains which in turn regulate the 
assembly of the actin-myosin stress fiber and focal adhesion (Gimona et al., 1996; 
Sanders et al., 1999).  These studies provide us a clue  as to the molecular basis of 
the role of myosin in the actin assembly in T2 overexpressing r-nmMHC-B.   
As mentioned earlier, overexpression of p53val135 did not readily induce 
transformation; rather, it induced instability of the host cells (reflected by their 
high spontaneous transformation rate).  T2 cell line was one of the spontaneously 
derived transformants that exhibited altered gene expression identified by the use 
of mRNA differential display technique (Yam et al., 1999).  Being one of the two 
genes found suppressed in T2 cells, the r-nmMHC-B is now also found to possess 
tumor suppression activity.  While the main focus of the current was on the effect 
and the possible mechanism of reexpression of the myosin gene, at the same time, 
it is equally important to the understanding of the initial cause of the suppression 
of r-nmMHC-B as well as the contribution of the p53val135 in the transition from 
non-transformed to transformed cells.  At present, the promoter activity of r-
nmMHC is being investigated in both R6#13-8 and T2 cells in our laboratory.   
Based on what is known in the field, p53 is neither a key component of spindle 
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assembly, nor does it play a direct role in the Rho/Rac signaling pathway through 
which the actin stress fibers form (Sablina et al., 1999; and Esteve et al., 1998).   
Lastly, it is worthwhile to mention that down-regulation of nmMHC-B 
was initially observed in, but not necessary restricted to, p53val135-transformed Rat 
6 cells.  As reported recently (Yam et al., 1999), suppression of the nmMHC-B 
was also observed  in Rat 6 cells transformed by c-H-ras, and partial suppression 
was also observed in v-myc, but not in those transformed by v-src, nor in mouse 
SVT2 cells expressing high levels of normal p53 gene. It would be interesting to 
explore whether the tumor suppression effects of nmMHC-B can be applied to 
malignant transformations induced by oncogenes other than mutant p53.   Such 
study should help to advance our understanding of the cellular function of 
nmMHC. 
 
Materials and Methods 
Cells and cell culture conditions.   
The Rat 6 embryo fibroblast cell line is a subclone of an immortalized F2408 rat 
embryo cell line (Freeman et al., 1967; Hsiao et al., 1986).  The R6#13-8 cell line 
is a derivative of the Rat 6 line infected with the retroviral vector pCH#13 
carrying a temperature-sensitive mutant p53val135 and the bacterial neomycin gene.  
R6#13-8 cells yield high levels of spontaneous transformation in prolonged 
cultures.  Clone T2 is one of the spontaneous transformants isolated from R6#13-
8 cells (Yam et al., 1999). The R6#8-2 cell line, a Rat 6 derivative expressing a 
retroviral backbone vector (Hsiao et al., 1992), was included in the experiment as 
a control cell line.  Both Rat 6 and R6#8-2 are anchorage independent and 
negative in nude mice assay (Hsiao et al., 1986; Housey et al., 1988).  All cell 
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lines were grown in Dulbecco's modified Eagle's medium (DMEM) (Gibco) 
supplemented with 10% calf serum (CS), penicillin, and streptomycin at 37°C in a 
humidified incubator with 5% CO2 in air.   
 
cDNA library screening and DNA sequencing.   
A 351-bp rat cDNA fragment corresponding to nucleotides 7107-7457 of human 
nmMHC (Phillips et al., 1995) was used as a probe to screen a rat brain cDNA 
library (Stratagene).  5 × 105 plaques were screened.  Hybridization was carried 
out at 42°C in 50% deionized formamide, 10% dextran sulfate, 1% SDS, and 1 M 
NaCl.  After three rounds of amplification, positive clones were selected and 
sequenced at both ends using an AutoRead™ sequencing kit (Pharmacia). 
Complete DNA sequencing was performed on both strands.  
 
Construction of expression vector and stable transfectants of r-nmMHC-B.   
A cDNA of 6.6 kb containing the entire open reading frame and partial 5’ and 3’ 
untranslated sequences of rat nmMHC-B was subcloned into an ecdysone 
inducible mammalian expression vector, pIND/Hygro (Invitrogen) at NotI and 
ApaI sites.  The resulting expression vector, pIND/nmHMC-B, was co-transfected 
with the pVgRXR (Invitrogen) carrying bacterial zeocin gene using 
LipoFectAMINE Plus reagent (BRL).  The stable transfectants were selected by 
cloning rings in a medium containing both hygromycin B (400 μg/ml) and zeocin 
(300 μg/ml).  
 
Antibodies and western blot analysis.   
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Confluent cultures in 60 mm dishes were washed with cold PBS three times and 
lysed in 400 μl NET buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 5 mM 
EDTA, pH 8.0, 1 mM APMSF, 1 μM E-64, 1 μM pepstatin, 100 mM NaVO5, and 
10 μg/ml aprotinin) plus 1% NP-40 on ice according to Lu et al. (1992).  For 
western blotting analysis, 10 μg of protein extracts were loaded on a 5% SDS-
PAGE.  After separation, the proteins were transferred to an Hybond-C nylon 
membrane (Amersham), reacted to rabbit anti-human nmMHC-A and -B 
polyclonal antibodies (supplied by Dr. R.S. Adelstein) and visualized by the ECL 
detection kit (Amersham) according to the instruction manual.   
 
Immunoflourescent staining.   
Immunofluorescent staining was performed according to Martinez et al. (1991) 
with slight modification. Cells grown on 1% gelatin-coated coverslips were rinsed 
three times in ice-cold PBS.  Cells were fixed in cold methanol for 5 min.  
Antibodies specific to human nmMHC-A and -B chains (supplied by Dr. R.S. 
Adelstein) were employed for immunofluorescent staining.  Specimens were 
mounted on glass slides with a mounting solution (20% glycerol in PBS). 
 
Growth curves and muristerone A treatment.   
Cells were seeded at 1.7x104 cells per 35 mm plate in triplicate and grown in 
DMEM plus 10% CS medium.  The following day, seeded cultures were given 
different concentrations of muristerone A.  Cell numbers were counted every 
other day. Mean values and standard deviations of the triplicates were calculated 
and plotted against time. 
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Soft agar assay.   
Tested cells were treated with or without muristerone A for 48 hr, then suspended 
at 1×104/60 mm plate with 2 ml of 0.4% Bacto-agar in DMEM containing 20% 
fetal calf serum (FCS) in the absence or presence of 1 or 5 μM of muristerone A 
and overlaid above a layer of 5 ml of 1% agar in the same medium in triplicate 
plates. Cells were refed with a top agar medium biweekly.  At day 28, colonies 
were stained with the vital stain 2-(p-iodopenyl)-3-(p-nitrophenyl)-5-
phenyltetrazolium chloride hydrate (INT) for 48 hr at 37°C in a 5% CO2 
incubator.  The number of colonies was scored using the Eagle Eye ®II System 
(Stratagene). 
 
Labelling of actin filaments.   
The cells were grown on coverslips were fixed with 3.7% formaldehyde in PBS 
for 10 mins at room temperature, then permeablized with 0.2% Triton X-100 in 
PBS for 1 min at room temperature, washed three times with PBS.  The cells were 
stained with FITC-phalloidin (Sigma) at 5 μg/ml in PBS for 30 mins at 37oC, then 
washed with PBS before mounting on microscopic slides with a drop of anti-
photobleaching Mowiel 4-88 (Calbiochem, USA) for examination under 
fluorescent microscope.  
 
Nude mice assay.   
For the in vivo tumorigenicity test, confluent cultures of tested cells were either 
induced or uninduced with 10 μM muristerone A for 48 hr. At the end of 
treatment, cells were harvested and washed with cold PBS once, then resuspended 
in fresh PBS and counted for cell numbers.   Triplicate s.c. inoculations with 
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3x106 cells were performed.  Experiments were monitored over a two-week 
duration. 
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Figure Legends 
 
Figure 1.  Expression of A- and B-isoforms of nmMHC in T2 and R6#13-8 cells.   
(A) Immunoblotting analysis: cell lysates were extracted from Rat 6, the parental 
cell line; R6#13-8, the untransformed Rat 6 clone overexpressing p53val135; and 
T2, the spontaneous transformant derived from R6#13-8 cells. Ten μg of each 
lysate were loaded per lane and separated by SDS-PAGE. The immunoblots were 
hybridized with anti-nmMHC-A and -B antibodies. (B) Immunofluorescent 
staining: cells were grown on gelatin-coated coverslips, fixed and incubated with 
anti-nmMHC-A and -B antibodies. Texas Red- and FITC-conjugated secondary 
antibodies were used in conjunction with nmMHC-A or -B antibodies 
respectively.  Cells were observed under a fluorescent microscope at 100× 
magnification.  Cos7 cells only express B-isoform and human platelets only 
express A-isoform.   
 
Figure 2.  Alignment of amino acid sequences of r-nmMHC-B (Rat) (GenBank 
AF139055) with those of human (Hum) (GenBank M69181) and chicken (Chk) 
(GenBank M93676) nmMHC-B.  Identical amino acid residues are indicated by 
dashes and amino acid residues different from that of r-nmMHC-B are shown.  
Locations of the two insertions in chicken nmMHC-B are indicated by the 
arrowheads (s).  The amino acid sequences of the two insertions are 
PESPKPVKHQ (insert after residue 211) and EIQNIQRACFYDNITGLHDPP 
(insert after residue 621).  The ATP binding site (a.a. 159-194), actin binding site, 
28-residue repeat (a.a.857-884) of the α-helical coiled core are underlined.  The 
α-helical core domain (a.a. 843-1933) is marked by the arrowbars. 
 
Figure 3. Characterizations of MHC-B#33 & MHC-B#44 clones expressing the 
acquired nmMHC-B gene.   (A) Western blot analysis. Cells were grown to 
subconfluency in 60 mm plates.  Each group was treated with 0, 1, 2, 5 or 10  μM 
of muristerone A for 48 hours before harvesting for cell lysate. Ten μg of cell 
lysate for each sample were loaded per lane and separated on SDS-PAGE and the 
resulting blot was reacted to anti-nmMHC-B antibody, detected by ECL detection 
system (Amersham).  Rat 6, R6#13-8, T2, T2C cells are included for comparisons. 
(B) Cell morphology.  All tested cell lines were maintained in growth medium in 
the absence of muristerone A.  Photographs were taken under the phase contrast 
field of a Zeiss Axiophot microscope at 40× magnification: (C) 
Immunofluorescent staining.  Semi-confluent cultures grown on coverslips were 
treated with or without muristerone A for 48 hrs, then fixed with cold methanol 
and immunostained with anti-MHC-B antibody followed by FITC-conjugated 
anti-rabbit antibody. a, b, c & e : no treatment;  d & f: treated with 5 μM 
muristerone A for 48 hr.  Photographs were taken under a fluorescent Zeiss 
Axiophot microscope using 100x objective in oil immersion.   
 
Figure 4. Comparison of growth properties of T2 and MHC#44 cells.  (A) left 
panel: Growth curves of MHC#44 cells treated with various dosage of 
muristerone A. Cells at 1.7x104 were seeded in six-well plates. Next day, cells 
were maintained in a growth medium supplemented with designated 
concentrations of muristerone A throughout the entire experiment.  Triplicate 
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wells were used for each time point.  Mean values of triplicates are calculated and 
plotted in semi-log graph. Error bars indicate standard deviations.  A “8 day” time 
pinot of T2 cells in the absence or presence of inducer is also included. (A) right 
panel: Dosage response curves of T2 & MHC#44 upon treatment of muristerone 
A.  The growth of each treatment group was presented as percent of growth 
relative to its respective no-treatment control.  (B) Anchorage-independent 
growth. 1×104 cells were seeded in 0.4% top agar containing DMEM plus 20% 
fetal calf serum.  Cells were refed with top agar medium supplemented with each 
designated concentration of muristerone A at day 14.  Experiments were 
terminated on day 28 and stained with INT-vital stain.  Colonies were counted 
and photographed with an Eagle Eye ®II image system (Stratagene). Soft agar 
colonies obtained from each group were calculated and presented as table form. 
Mean values and standard deviations of triplicates of each group are shown.  (C) 
Representations of soft agar colonies of T2 and MHC#44 cells with and without 
the inducer.  An average size of the colonies derived from each group is displayed  
in this panel.  The scale bar in white color is 0.1 mm in length. 
 
Figure 5.  Localization of actin filament bundles in various cells using FITC-
conjugated phalloidin.  A. Rat 6 cells, B. R6#13-8, C. T2C, and D. MHC#44 cells. 
Photographs were taken under a fluorescent Zeiss Axiophot microscope using 
100x objective in oil immersion.  
 
Figure 6.  Comparison of the tumorigenicity of T2 and MHC#44 in nude mice.  
Cells  were treated with 10 μM muristerone A for 48 hrs and washed with PBS. 
Each group of cells was inoculated at 3x106 per site. Experiments were carried 
out for two weeks.  Pictures were taken two week after the animal received 
injections. 
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